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Persistent human immunodeficiency virus type 1 (HIV-1) infection of resting CD4 T cells, unaffected by antiretroviral therapy
(ART), provides a long-lived reservoir of HIV infection. Therapies that target this viral reservoir are needed to eradicate HIV-1
infection. A small-animal model that recapitulates HIV-1 latency in resting CD4 T cells may accelerate drug discovery and
allow the rational design of nonhuman primate (NHP) or human studies. We report that in humanized Rag2/ c/ (hu-
Rag2/ c/) mice, as in humans, resting CD4 T cell infection (RCI) can be quantitated in pooled samples of circulating cells
and tissue reservoirs (e.g., lymph node, spleen, bone marrow) following HIV-1 infection with the CCR5-tropic JR-CSF strain and
suppression of viremia by ART. Replication-competent virus was recovered from pooled resting CD4 T cells in 7 of 16 mice,
with a median frequency of 8 (range, 2 to 12) infected cells per million T cells, demonstrating that HIV-1 infection can persist
despite ART in the resting CD4 T cell reservoir of hu-Rag2/ c/ mice. This model will allow rapid preliminary assessments
of novel eradication approaches and combinatorial strategies that may be challenging to perform in the NHP model or in hu-
mans, as well as a rigorous analysis of the effect of these interventions in specific anatomical compartments.
Human immunodeficiency virus type 1 (HIV-1) infection per-sists despite years of antiretroviral therapy (ART) (16, 18, 28).
Proviral latency is established early in infection, even in patients
who are treated with ART within the first weeks of infection (13).
Latently infected memory CD4 T cells constitute the major res-
ervoir of viral persistence in patients on ART (13, 18, 20, 28, 33)
and can replenish systemic infection following interruption of
therapy (15). Eliminating HIV-1 latency in this important reser-
voir is critical to the pursuit of successful eradication strategies.
HIV-1 infection also may persist in a variety of anatomical
compartments, such as the central nervous system (CNS), a phar-
macologically “privileged” site where the blood-brain barrier lim-
its the penetration of some antiretrovirals and may provide a sanc-
tuary for viral persistence (23). The gut-associated lymphoid
tissue (GALT), a site where drug metabolism is poorly under-
stood, has also been suggested to be a source of persistent infection
during ART (17). Bailey and colleagues found that viral genomes
represented in low-level, persistent viremia despite ART were
sometimes different than those found in resting CD4 T cells (5),
but Anderson et al. found a concordance of circulating and resting
cell viral isolates (1). Primitive hematopoietic cells were shown to
resist HIV-1 infection (37), but recent studies claim that HIV-1
infection of multipotent progenitor cells could be a potential
source of persistent infection by CXCR4-tropic viruses (11).
These findings highlight the need for systems in which a compre-
hensive analysis of all possible cells and reservoirs that may harbor
persistent HIV can be examined. Such studies are difficult to con-
duct in humans and may be better addressed in animal models of
HIV-1 latency.
Currently, the macaque nonhuman primate (NHP) model of
simian immunodeficiency virus (SIV) infection on ART is the
only animal model available to study HIV-1 latency and persis-
tence (19, 32). Although HIV-1 is closely related to SIV, unique
accessory proteins and sequence variation within homologous
proteins of this lentivirus may subtly alter the pathogenesis of
persistent infection (36). While the macaque NHP model of SIV is
important for the study of HIV persistence, given the limited re-
sources available for the study of macaques, progress could be
accelerated by a tractable animal model that recapitulates resting
CD4 T cell infection. Such a model will allow a rigorous evalua-
tion of preclinical strategies to eradicate HIV-1 infection in tissue
reservoirs. Human studies are usually slow and difficult and pose
some risks to patients who are otherwise clinically stable. A small-
animal model of latency would allow additional preclinical studies
to be performed, helping to focus human trials seeking to purge
latent reservoirs.
Persistent HIV-1 infection has been demonstrated in CD4
thymocytes in the SCID-hu (Thy/Liv) mouse model, but these
animals possess few resting CD4 T cells in the peripheral blood
(PB) and secondary lymphoid tissues (9, 10). A humanized mouse
model that carries resting memory CD4 T cell infection in the PB
and secondary lymphoid tissues may be better suited for the test-
ing of HIV-1 eradication strategies.
Humanized Rag2/ c/ (hu-Rag2/ c/) mice, first de-
veloped by Traggiai and colleagues, show stable reconstitution of
human T, B, natural killer (NK), and dendritic cells in both pri-
mary and secondary lymphoid organs (35). These mice are readily
infected with HIV-1, resulting in high-level plasma viremia and
depletion of CD4 T cells in the PB (4, 7, 12, 38). We and others
have demonstrated that plasma viremia can be suppressed below
the limit of detection with ART (12, 31). The discontinuation of
ART results in viral rebound, suggesting the presence of persistent
infection (12). In our current study, we show that intensification
of a 3-drug ART regimen with enfuvirtide improved suppression
of plasma viremia, prevented the emergence of drug resistance,
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and allowed the recovery of resting CD4 T cells that expressed
HIV only after ex vivo stimulation. This is the first tractable small-
animal model of HIV-1 infection, ART, and latency.
MATERIALS AND METHODS
Ethics statement. All animal work was approved by the University of
North Carolina Institutional Animal Care and Use Committee (IACUC).
Human fetal liver was obtained from Advance Bioscience Resources (Al-
ameda, CA), a nonprofit organization, in accordance with federal and
state regulations.
Generation and maintenance of hu-Rag2/ c/ mice. hu-
Rag2/ c/ mice were created by transplanting human fetal liver-
derived CD34 cells into the livers of newborn conditioned Rag/ c/
mice as described previously (35, 38), with minor modifications. Briefly,
human fetal liver at 16 to 24 weeks of gestation was treated with 1 mg/ml
collagenase D and 10 g/ml DNase I (Roche, Indianapolis, IN) for 1 h at
37°C and filtered through a 70-m cell strainer (BD, Franklin Lakes, NJ)
to make a single-cell suspension. Mononuclear cells were enriched on
Ficoll-Paque Plus (GE Healthcare, Piscataway, NJ), and human CD34
cells were purified to more than 95% purity using a CD34 selection kit
(Stemcell Technologies, Vancouver, Canada) according to the manufac-
turer’s instructions. Cells were cultured overnight in RPMI 1640 medium
containing 20% fetal bovine serum (FBS), 1 g/ml interleukin 3 (IL-3), 1
g/ml IL-6, and 2 g/ml stem cell factor (R&D Systems, Minneapolis,
MN). The next day, 0.5  106 to 1  106 human CD34 cells were injected
intrahepatically into newborn mice (1 to 3 days old) previously irradiated
with 300 rad (X-Rad 320; Precision X-Ray, North Branford, CT). Ten to
12 weeks posttransplantation, the level of human leukocytes in the periph-
eral blood (PB) was determined by flow cytometry. All mice were main-
tained in microisolator cages on racks with HEPA-filtered air blown into
each cage.
Flow cytometric analysis of human leukocytes in PB and tissue. PB
samples were collected by tail vein bleeding and lysed with ACK lysis
buffer (Invitrogen, Carlsbad, CA). Mononuclear cells from bone marrow
(BM), thymus, spleen, lymph node (LN), the female reproductive tract
(FRT), lung, and liver were collected as described previously (25). Cells
were incubated with the appropriate antibodies in 1 phosphate-
buffered saline (PBS) containing 2% FBS plus 0.02% sodium azide,
washed, and fixed in 200 l PBS with 2% formaldehyde overnight prior to
flow cytometry. Cells were analyzed using a CyAn ADP flow cytometer
and Summit 4.3 software (Beckman Coulter Inc., Miami, FL). Human
leukocytes (CD45 cells) were analyzed for surface expression of CD3,
CD4, CD8, CD45RO, CD45RA, CD62L, CD27, HLA-DR, CD25, and
CD69. Unstained cells or cells stained with an appropriate isotype control
were used to set markers defining positive reactivity. The following
anti-human monoclonal antibodies were used: fluorescein isothiocya-
nate (FITC)-conjugated CD8, CD69 (Invitrogen, Carlsband, CA),
CD4, and CD27 (BD Pharmingen, San Diego, CA); phycoerythrin
(PE)-conjugated CD4 and CD25 (Invitrogen, Carlsband, CA);
peridinin-chlorophyll protein (PerCP)-conjugated CD3 and HLA-DR
(BD Pharmingen, San Diego, CA); phycoerythrin cyanine 5.5 (PE-
Cy5.5)-conjugated CD45RA (BD Pharmingen, San Diego, CA); allo-
phycocyanin (APC)-conjugated CD45 (Invitrogen, Carlsband, CA);
CD62L and CD45RO (BD Pharmingen, San Diego, CA); and allophy-
cocyanin cyanin Cy7 (APC-Cy7)-conjugated CD45 and CD11b (BD
Pharmingen, San Diego, CA). Pacific blue-conjugated anti-mouse
CD45 was obtained from BioLegend (San Diego, CA).
HIV-1 infection and ART in hu-Rag2/ c/ mice. hu-Rag2/
c
/ mice with stable human leukocyte reconstitution (with a 10% or
higher percentage of human CD45 T cells in at least two determinations,
2 weeks apart) were infected with the CCR5-tropic HIV-1 clone JR-CSF
(25 ng p24/mouse) by retro-orbital injection. Plasma viremia was assayed
with the use of the Abbott RealTime reverse transcription-PCR (RT-PCR)
automated m2000 system (Abbott Molecular Inc., Des Plaines, IL). In-
fected mice were treated daily with intraperitoneal injections of combined
emtricitabine (FTC), tenofovir (TFV), and L-870812 (60, 60, and 20
mg/kg of body weight, respectively, in a volume of 150 l) reconstituted in
PBS, pH 11. Mice also received daily subcutaneous injections of enfu-
virtide (100 mg/kg of body weight) reconstituted in water. Mice were bled
by tail nicking, and the plasma viral loads and PB cell populations were
assayed periodically. Due to a limited volume of plasma available at pre-
terminal bleeds (50 to 100 l), samples were expanded by dilution for
assay in the Abbott system. The limit of detection in this assay is 40 cop-
ies/ml or less, but due to dilution, the limit of detection of our assays was
500 to 800 copies/ml, depending on the available sample volume. Mice
with suppressed plasma viral loads below this level of detection for at least
2 weeks were used in terminal experiments to determine the frequency of
resting CD4 T cell infection (RCI), and plasma viremia was measured in
a large bleed volume at the time of sacrifice.
Purification of resting CD4 T cells from hu-Rag2/ c/ mice.
Human leukocytes from spleen, BM, liver, lung, FRT, and PB were en-
riched on 40 to 70% Percoll gradients by centrifugation (Percoll plus; GE
Healthcare, Piscataway, NJ). As the thymus and LN already contain high
percentages of human leukocytes, these tissues were not subjected to Per-
coll enrichment to minimize cell loss. Cells were pooled from all tissues
and resuspended at 5 million cells/ml in separation medium (Ca2- and
Mg2-free PBS containing 2% FBS), and human resting CD4 T cells
were enriched using a mouse/human enrichment kit (Stemcell Technol-
ogies, Vancouver, Canada), with modifications. Briefly, cells were incu-
bated with a mouse/human enrichment cocktail (35 l/ml) supplemented
with anti-mouse biotinylated CD31 and CD105 antibodies (0.5 g/ml
each; eBioscience Inc., San Diego, CA), washed once with separation me-
dium, and then incubated for 15 min with anti-biotin tetrameric antibody
complex (TAC). Additionally, a custom TAC-conjugated human anti-
body cocktail (CD8, CD14, CD16, CD19, CD56, glycophorin A, CD41,
HLA-DR, and CD25) (Stemcell Technologies, Vancouver, Canada) was
added at this step to enrich human resting CD4 T cells. Following incu-
bation with magnetic colloids, cells were subjected to column chromatog-
raphy to purify the human resting CD4 T cell population by negative
selection.
Viral outgrowth assay and determination of the frequency of RCI.
Purified cells were cultured in RPMI 1640 medium containing 20% FBS,
15 nM efavirenz, and 1 M raltegravir at high densities (3 to 5 million
cells/ml) for 2 to 3 days in U-bottom, 96-well culture plates. The presence
of active viral replication in the culture supernatant was determined by
p24 assay before phytohemagglutinin (PHA) stimulation. Cells were
washed and plated at 10,000 to 100,000 cells/well in 12-well culture plates
and maximally activated for 2 days with 1 g/ml PHA, 100 units/ml IL-2,
and a 10-fold excess of irradiated peripheral blood mononuclear cells
(PBMCs) from an HIV-seronegative donor. Control cultures received
only 20 units/ml of IL-2. Cultures were fed twice with CD8-depleted,
PHA-stimulated PBMCs. The culture supernatant was removed every 3 to
4 days and replaced with an equivalent volume of fresh medium contain-
ing 20 units/ml IL-2. We scored cultures as positive if p24 was detectable
at 15 days following stimulation and confirmed on day 19. RCI frequency
was estimated by a maximum likelihood method and is expressed as the
number of infectious units per million resting CD4 T cells (IUPM) (2).
RESULTS
Resting CD4 T cells constitute the predominant cell popula-
tion in the lymphoid tissue of hu-Rag2/ c/ mice. Second-
ary lymphoid tissues are the sites where the majority of lympho-
cytes reside in humans. They are also the sites of antigen
presentation and lymphocyte activation and therefore a critical
venue for HIV-1 replication and establishment of HIV-1 latency
(29). We, therefore, enumerated human resting CD4 T cells in
several secondary lymphoid tissues, including LN, spleen, and
BM, in hu-Rag2/ c/ mice with stable human-cell engraft-
ment in PB (10% of the engrafted cells in PB were human
CD45 cells) at 12 to 14 weeks posttransplantation. We observed
HIV-1 Latency in a Humanized Mouse Model
January 2012 Volume 86 Number 1 jvi.asm.org 115
the presence of several mesenteric and cervical LNs in these hu-
manized mice. Axillary, brachial, and superficial inguinal LNs
were also present, but infrequent. LNs were highly reconstituted
with human cells; 70% (median; range, 56 to 82%) of cells present
in the LNs of four mice were human CD45 cells. Forty to 60% of
the engrafted human cells were CD4 T cells, and more than 48%
uniformly expressed CD45RO but lacked CD62L, suggesting that
they were memory cells (Fig. 1). Furthermore, greater than 75% of
CD4 T cells lacked early (CD25, CD69) and late (HLA-DR) ac-
tivation markers, suggesting that they were resting cells. Spleen
and BM were also significant sources of engrafted human cells
(range, 50 to 72% of total human cells engrafted). As in the LNs,
the majority of human cells in the spleen and BM were resting
memory CD4 T cells (Fig. 1). Human CD45 T cells were also
recovered from liver, lung, and the female reproductive tract
(FRT), but they constituted less than 5% of the total human cells
in the mice. Very rare human CD4 T cells were found in the
gut-associated lymphoid tissue (GALT) of this humanized mouse
model. Therefore, it appears that LN, spleen, and BM are the ma-
jor sources of resting memory CD4 T cells in the lymphoid tissue
of hu-Rag2/ c/ mice.
In contrast to lymphoid tissue, PB contained more naïve CD4
T cells than memory cells (Fig. 1). The majority of CD4 T cells in
PB also lacked the activation markers CD69, CD25, and HLA-DR.
CD11b myeloid cells were detected in several lymphoid tis-
sues at frequencies ranging from 1.4 to 7.6% in four mice. How-
ever, less than 0.2% of the total human cells were CD14 in BM
and LN, and only 0.5% of these cells were observed in the spleen,
suggesting that macrophages are a minor population in this hu-
manized mouse model at 12 to 14 weeks posttransplantation. We
therefore conclude that resting CD4 T cells constitute the pre-
dominant cell population in the lymphoid and peripheral tissue of
hu-Rag2/ c/ mice; these cells are critical for the establish-
ment and maintenance of persistent HIV-1 infection in humans.
Suppression of HIV-1 plasma viremia with ART. Infection of
hu-Rag2/ c/ mice with CCR5-tropic HIV-1 JR-CSF re-
sulted in productive HIV-1 replication in all mice at 12 to 14 days
postinfection. We have previously reported that 3-drug ART com-
prised of the HIV nucleoside/nucleotide reverse transcriptase in-
hibitors (NRTIs) FTC and tenofovir (TFV) and the HIV integrase
strand transfer inhibitor (InSTI) L-870812 at doses of 60, 50, and
20 mg/kg/day, respectively, suppresses HIV-1 plasma viremia be-
low the limit of detection after 7 to 9 weeks of treatment (12).
However, one mouse out of six in this earlier study failed therapy
FIG 1 Characterization of human CD4 (huCD4) T cell reconstitution in lymphoid tissues and peripheral blood (PB). Cells from mesenteric lymph nodes,
bone marrow, and spleen were harvested at 14 weeks posttransplantation and characterized by flow cytometric analysis. Live cells were discriminated based on
forward and side scatter and gated on human CD45/mouse CD45 cells to quantitate human-cell reconstitution in each tissue (shown in parentheses). (A)
Human CD45 cells were gated on CD3 cells to analyze CD4/CD8 T cells. (B and C) CD4 T cells were characterized as naïve or memory cells based on
expression of CD62L or the CD45RO antigen, respectively. (C and D) The resting state of CD4 cells was determined by the lack of activation markers CD25,
CD69, and HLA-DR. Data are representative of results from 5 uninfected animals.
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due to the emergence of drug resistance mutations selected by
tenofovir disoproxil fumarate (TDF) (K65R) and InSTIs (M154I).
In our current study, ART was intensified with a fourth drug,
enfuvirtide, a fusion inhibitor. The 4-drug ART regimen more
rapidly suppressed plasma viremia, and viremia was below the
limit of assay detection (500 to 800 copies/ml) (see Materials and
Methods) in 15 out of 16 mice within 5 weeks, 2 to 4 weeks more
rapidly than previously observed with a 3-drug ART regimen (Fig.
2). Although HIV was subsequently undetectable in most animals,
occasional surges of viremia similar to the “blips” reported clini-
cally were observed in a few mice (27). One animal (121-7) had
detectable viremia after 64 days of treatment. Nevertheless, even
in this animal, we observed a gradual and continuous decline in
plasma viremia.
At the time of necropsy, larger volumes of plasma were col-
lected, allowing the detection of lower levels of viremia in 6 of 8
mice. However, two mice had plasma viremia levels below 40 cop-
ies/ml. A viral blip was observed in mouse 127-6 at the time of
necropsy. The observation of low but continually declining
viremia after 9 weeks or less of ART is consistent with viral dynam-
ics seen in human studies (26).
Suppression of viremia following ART allowed recovery of hu-
man CD4 T cells in the PB of several mice, including 107-1,
121-6, 121-7, and 124-2. However, little CD4 T cell recovery was
detected in four animals on ART. Overall, these data show that
4-drug ART allows rapid suppression of plasma viremia and some
recovery of CD4 T cells in hu-Rag2/ c/ mice, analogous to
the experience of ART-treated HIV-1-infected patients.
Quantitation of RCI in ART-suppressed hu-Rag2/ c/
mice. We sought to quantitate the frequency of RCI in ART-
suppressed humanized mice in the pooled cells of peripheral
blood and other lymphoid tissue, as mentioned in Materials and
Methods. We recovered human cells following column purifica-
tion, with 8% murine contaminants (Fig. 3A and B). More than
99% of human cells were CD3 T cells with no detectable CD19
and CD11b cells, demonstrating the successful exclusion of B
cells, macrophages, and NK cells by column purification (Fig. 3
and data not shown). Virtually all T cells were CD4 cells and
lacked the activation markers CD25 and HLA-DR, identifying
them as resting cells. We further characterized the resting CD4 T
cells based on CD27 and CD45 expression and observed that the
vast majority were central memory cells (Fig. 3B). The median
FIG 2 Suppression of HIV-1 plasma viremia with ART in hu-Rag2/ c/ mice. Mice were infected with JR-CSF (25 ng p24/mouse) and treated with the
nucleoside/nucleotide reverse transcriptase inhibitors emtricitabine (FTC) and tenofovir (TFV), the integrase strand transfer inhibitor L-870812, and the fusion
inhibitor enfuvirtide (60, 60, 20, and 100 mg/kg/daily, respectively). BI, time before infection. The arrows indicate the initiation of ART, the blue lines and
triangles show plasma viremia, while the green lines and squares show the percentages of all PBMCs that are human CD3 CD4 T cells. The blue dotted lines
show the limit of detection (800 copies/ml) of plasma viremia in 50 to 100 l of samples obtained through the tail vein. The filled markers below the dotted lines
indicate detection of plasma viremia in higher sample volumes at necropsy (limit of detection, 40 copies/ml).
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recovery of resting CD4 T cells following column purification
was 450,000 cells, with a range of 110,000 to 800,000 cells.
To validate that the resting CD4 T cells isolated did not ex-
press HIV, cells from all of the mice except 105-1, 106-4, 107-1,
and 111-1 were cultured for 2 to 3 days without stimulation and
immediately tested for HIV-1 expression. No HIV gag p24 antigen
was detected in these cultures, suggesting the absence of ongoing
viral replication (22). To demonstrate that resting cells contained
replication-competent HIV-1, the resting cells were maximally
activated with PHA and cocultured with CD8-depleted activated
PBMCs. Virus was recovered from resting CD4 T cell cocultures
of seven mice following stimulation with PHA (Table 1). Control
cocultures performed with cells that were not maximally activated
but that were incubated with a low concentration of IL-2 (20
U/ml) sufficient to support cell survival were negative, demon-
strating that full activation is usually necessary to disrupt latency
and recover replication-competent HIV (14). The outgrowth of
HIV from none of the 8 activated cocultures but 1 of the 4 IL-2-
supported cocultures (in mouse 111-1) likely reflects a chance
event in the context of a low frequency of infected resting CD4
cells, similar to results seen in coculture assays from humans (3).
All mice were treated with ART for 50 to 102 days, and all
except mouse 121-7 had no detectable plasma viremia for at least
24 days. The frequency of RCI, when it could be measured, varied
in each mouse, ranging from 2 to 12 IUPM, with a median of 8
TABLE 1 Recovery of replication-competent HIV-1 from latently
infected resting human CD4 T cells after mitogen activation
Mouse















111-2 64 2/8 0/4 7
116-1 52 2/7 ND 8
116-9 52 3/9 0/2 10
121-6 52 2/9 0/4 6
127-3 58 1/4 ND 12
124-2 102 1/11b 0/2 2
135-1 102 2/5c ND 12
111-1 64 0/6 1/4 7
105-1 90 0/4 0/4 7
106-4 90 0/4 0/4 7
107-1 90 0/4 ND 7
121-7 52 0/8 ND 3
127-2 58 0/4 ND 11
127-5 58 0/2 ND 37
127-6 58 0/2 ND 37
134-10 102 0/7d ND 6
a ND, not determined.
b Limiting dilution of 100,000 to 25,000 cells, with a total of 650,000 cells.
c Limiting dilution of 100,000 to 10,000 cells, with a total of 245,000 cells.
d Limiting dilution of 40,000 to 15,000 cells, with a total of 230,000 cells.
FIG 3 Isolation of resting CD4 T cells from humanized mice. Resting CD4 T cells were isolated from pooled blood and lymphoid tissues of each mouse by
negative selection. Cells before (A) and after (B) magnetic bead enrichment are shown. CD4 T cells lacked the activation markers CD25 and HLA-DR and were
predominantly central memory cells (CD27 CD45RA). mCD45, mouse CD45 cells.
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IUPM. Resting CD4 T cells from the other nine mice yielded no
replication-competent virus, but as fewer cells were available in
many of these animals, the lack of detection of virus means that
the frequency of RCI ranged from less than 3 to less than 37 in-
fected cells per million total cells. If the data for all mice studied are
pooled, the estimated RCI frequency is 3.8 infected cells per mil-
lion.
DISCUSSION
In this study, we treated hu-Rag2/ c/ mice with intensified
ART to model the HIV-1 latency in resting CD4 T cells observed
in patients. This humanized mouse model supports HIV-1 repli-
cation and CD4 T cell depletion after infection with both CCR5-
and CXCR4-tropic HIV-1 and displays long-term chronic infec-
tion (4, 6, 7, 38). Here, we report that memory CD4 T cells
constitute the major cell population in several lymphoid tissues,
including the LN, spleen, and BM, 14 to 16 weeks after transplan-
tation. Zhang and colleagues also observed that about 28% of cells
were CD45RO memory CD4 T cells in both HIV-1-infected
and uninfected animals (38). We report that the majority of mem-
ory CD4 T cells lacked activation markers, such as CD25, CD69,
and HLA-DR, suggesting that the lymphoid tissues in this human-
ized mouse provide the milieu necessary for the maintenance of
resting memory CD4 T cells. We speculate that these resting cells
might support an RCI within lymphoid tissue similar to that ob-
served in HIV-1-infected patients.
To mimic RCI during ART in humans, HIV-1-infected mice
were treated with a 4-drug ART regimen. In the macaque SIV
model, 4-drug ART was also used to rapidly suppress viremia (19).
The 4-drug ART regimen more reliably suppressed viremia than
the 3-drug ART regimen previously reported (12). The new regi-
men suppressed viremia to below the level of detection in 2 to 5
weeks of treatment. Furthermore, suppression of viremia not only
prevented further decline in CD4 T cells but also resulted in an
increased CD4 T cell percentage in the PB of several mice. Zhang
and colleagues observed an increase in the number of CD4 T
cells in the PB during low-level viral infection without ART, indi-
cating the presence of a responsive and functional human im-
mune system in this humanized mouse model (38).
We were able to purify human cells from hu-Rag2/ c/
mice by negative selection, and more than 98% of the human cells
were resting CD4 T cells. The activation of resting CD4 T cells
isolated from pooled tissue and cocultured with CD8-depleted
PBMCs allowed recovery of replication-competent virus in sev-
eral suppressed mice. Resting cells were cultured for 2 to 3 days in
the presence of raltegravir and efavirenz before viral outgrowth to
facilitate the degradation or circularization of the labile preinte-
gration complex and to exclude the possibility that preintegration
latency might contribute to the recovery of virus (30). No
CD11b cells were detected following column purification, and
therefore, macrophages and NK cells could not contribute to the
recovery of persistent HIV. In culture, about 7% of the total cells
were of murine origin, but these cells are refractory to HIV-1
replication due to several restrictions at the entry, transcription,
and assembly stages of the viral life cycle (8, 21, 24). Together,
these results suggest that latently infected resting CD4 T cells
were indeed the source of persistent infection in this mouse
model.
The median frequency of RCI was 8 (range, 2 to 12) infected
cells per million (IUPM) in seven mice treated with ART for 52 to
102 days. Resting CD4 T cells from the other nine mice yielded
no replication-competent virus on mitogen activation, but as
fewer cells were available in many of these animals, the lack of
detection of virus means that the frequency of RCI ranged from
less than 3 to less than 37 infected cells per million cells. The RCI
frequencies in these two cohorts therefore overlap and are similar
to that seen in humans (33) and most similar to the RCI frequency
of patients treated for a few months after acute HIV infection (34).
If the data for all mice studied are pooled, the estimated RCI is 3.8
infected cells per million cells. Cultures supplemented with IL-2
(20 ng/ml) but not treated with mitogen yielded no viral out-
growth in any case except for a single culture from mouse 111-1.
This likely reflects a chance event in the context of a low frequency
of infected resting CD4 cells. We have similarly observed that
suboptimal concentrations of IL-2 can sometimes induce infre-
quent viral production in resting CD4 cells from aviremic pa-
tients (14).
It has been well established that most of the proviral DNA
integrated in the genome of a host on ART has intrinsic defects
and that only 1% of HIV-1 DNA-positive CD4 T cells can be
induced to high-level HIV-1 gene expression after cellular activa-
tion (22). Limited numbers of human T cells are available in hu-
manized mice to yield the purified resting CD4 T cells needed to
perform viral outgrowth assays. Therefore, we elected to focus on
direct measurements of the frequency of resting CD4 T cell in-
fection and did not expend valuable cells to make surrogate mea-
surements. This has allowed us to make direct comparisons of
resting CD4 T cell infections in humanized mice on suppressive
ART with those in patients on ART and will ultimately allow pre-
cise testing of the effect of novel antilatency reagents.
In the SIV-infected macaque model of viral latency, a high RCI
frequency in the PB was observed in suppressed animals at 64 and
99 days after ART, but it declined to 1.1 infected cells per million
after 150 days of treatment (19). The number of IUPM in the
lymphoid tissue was slightly higher than that in the PB of the
monkey model, with 1.8 and 1.4 IUPM observed in spleen and gut
LNs, respectively (19). It is likely that treatment of infected mice
with ART for a shorter time (56 to 90 days), as well as the predom-
inance of resting CD4 T cells in the lymphoid tissue, might have
contributed to a higher frequency of RCI.
In summary, this study validates hu-Rag2/ c/ mice as a
model of persistent HIV-1 infection after suppressive ART. More-
over, our results suggest that HIV-1 infection persists in central
memory CD4 T cells, a reservoir of known importance for the
eradication of HIV-1 infection in humans. Since these mice are
highly reconstituted with memory CD4 T cells, this model may
be amenable to rigorous testing of novel therapeutic approaches
before their application to HIV-1-infected patients. We have be-
gun such studies. Our study thus provides a foundation for further
optimization, such as improvements in the recovery of resting
cells or in the pooling of cells from identical mice within a cohort,
and points the way for studies of models of eradication of HIV-1
infection.
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